20 Sep TATAA Biocenter
Founded in 2001 by pioneers in molecular analyses, TATAA Biocenter (“TATAA”) offers a full range of qPCR, dPCR and Next-Generation Sequencing (NGS) services to biopharma sponsors. TATAA also offers services based on proprietary technologies, such as Two-Tailed PCR analysis of nucleic acids and Direct Blood Genotyping. TATAA leads the market with quality: Having participated in international efforts such as SPIDIA/SPIDIA4P and CANCER-ID, TATAA has contributed to the drafting of multiple international ISO and CEN guidelines, as well as the MIQE and dMIQE guidelines for the research community. With a lab purpose-built for GLP compliance and flexible ISO 17025 accreditation, TATAA is positioned to support biopharma sponsors with pharmacokinetic (PK), pharmacodynamic (PD) and biodistribution studies in the areas of Cell and Gene Therapies, Advanced Therapy and Medical Products (ATMP), and RNA Therapeutics. www.tataa.com
